{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:17:04Z","timestamp":1793593024010,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR001882"],"award-info":[{"award-number":["KL2TR001882"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["938451"],"award-info":[{"award-number":["938451"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1K01AI180591"],"award-info":[{"award-number":["1K01AI180591"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI141202"],"award-info":[{"award-number":["R01AI141202"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32488-8","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:18:45Z","timestamp":1765837125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections"],"prefix":"10.1038","volume":"16","author":[{"given":"Shakti","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman G.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Barbarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Hautau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunna","family":"Nabeela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teclegiorgis","family":"Gebremariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondus","family":"Alkhazraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Ostroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"32488_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1086\/520194","volume":"29","author":"MS Rangel-Frausto","year":"1999","unstructured":"Rangel-Frausto, M. S. et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin. Infect. Dis. 29, 253\u2013258. https:\/\/doi.org\/10.1086\/520194 (1999).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1086\/507539","volume":"43","author":"NE Aronson","year":"2006","unstructured":"Aronson, N. E., Sanders, J. W. & Moran, K. A. Emerging infections: in harm\u2019s way: infections in deployed American military forces. Clin. Infect. Dis. 43, 1045\u20131051. https:\/\/doi.org\/10.1086\/507539 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.7205\/milmed.170.6.521","volume":"170","author":"DR Harman","year":"2005","unstructured":"Harman, D. R., Hooper, T. I. & Gackstetter, G. D. Aeromedical evacuations from operation Iraqi freedom: a descriptive study. Mil Med. 170, 521\u2013527. https:\/\/doi.org\/10.7205\/milmed.170.6.521 (2005).","journal-title":"Mil Med."},{"key":"32488_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/jramc-152-02-06","volume":"152","author":"DE Hinsley","year":"2006","unstructured":"Hinsley, D. E., Phillips, S. & Clasper, J. C. Ballistic fractures during the 2003 Gulf conflict - early prognosis and high complication rate. J. R Army Med. Corps. 152, 96\u2013101. https:\/\/doi.org\/10.1136\/jramc-152-02-06 (2006).","journal-title":"J. R Army Med. Corps"},{"key":"32488_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.7205\/milmed.171.9.826","volume":"171","author":"CK Murray","year":"2006","unstructured":"Murray, C. K. et al. Bacteriology of war wounds at the time of injury. Mil Med. 171, 826\u2013829. https:\/\/doi.org\/10.7205\/milmed.171.9.826 (2006).","journal-title":"Mil Med."},{"key":"32488_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.7205\/milmed-d-03-8008","volume":"174","author":"CK Murray","year":"2009","unstructured":"Murray, C. K. et al. Recovery of multidrug-resistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil Med. 174, 598\u2013604. https:\/\/doi.org\/10.7205\/milmed-d-03-8008 (2009).","journal-title":"Mil Med."},{"key":"32488_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajic.2009.05.007","volume":"38","author":"F Perez","year":"2010","unstructured":"Perez, F. et al. Antibiotic resistance determinants in acinetobacter spp and clinical outcomes in patients from a major military treatment facility. Am. J. Infect. Control. 38, 63\u201365. https:\/\/doi.org\/10.1016\/j.ajic.2009.05.007 (2010). 2009\/09\/24.","journal-title":"Am. J. Infect. Control"},{"key":"32488_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10096-003-0890-x","volume":"22","author":"H Alonso-Valle","year":"2003","unstructured":"Alonso-Valle, H. et al. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur. J. Clin. Microbiol. Infect. Dis. 22, 254\u2013257. https:\/\/doi.org\/10.1007\/s10096-003-0890-x (2003).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"32488_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1086\/374621","volume":"187","author":"KB Laupland","year":"2003","unstructured":"Laupland, K. B., Church, D. L., Mucenski, M., Sutherland, L. R. & Davies, H. D. Population-based study of the epidemiology of and the risk factors for invasivestaphylococcus aureusinfections. J. Infect. Dis. 187, 1452\u20131459. https:\/\/doi.org\/10.1086\/374621 (2003).","journal-title":"J. Infect. Dis."},{"key":"32488_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/archinte.159.13.1437","volume":"159","author":"AG Jensen","year":"1999","unstructured":"Jensen, A. G. et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch. Intern. Med. 159, 1437. https:\/\/doi.org\/10.1001\/archinte.159.13.1437 (1999).","journal-title":"Arch. Intern. Med."},{"key":"32488_CR11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s100960000325","volume":"19","author":"R Luzzati","year":"2000","unstructured":"Luzzati, R. et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 19, 602\u2013607. https:\/\/doi.org\/10.1007\/s100960000325 (2000).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"32488_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/archsurg.136.12.1401","volume":"136","author":"PS McKinnon","year":"2001","unstructured":"McKinnon, P. S. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch. Surg. 136, 1401. https:\/\/doi.org\/10.1001\/archsurg.136.12.1401 (2001).","journal-title":"Arch. Surg."},{"key":"32488_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3109\/00365549409008638","volume":"26","author":"CH Debusk","year":"1994","unstructured":"Debusk, C. H., Daoud, R., Thirumoorthi, M. C., Wilson, F. M. & Khatib, R. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand. J. Infect. Dis. 26, 697\u2013703. https:\/\/doi.org\/10.3109\/00365549409008638 (1994).","journal-title":"Scand. J. Infect. Dis."},{"key":"32488_CR14","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s00134-003-2002-x","volume":"29","author":"PE Charles","year":"2003","unstructured":"Charles, P. E. et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 29, 2162\u20132169. https:\/\/doi.org\/10.1007\/s00134-003-2002-x (2003).","journal-title":"Intensive Care Med."},{"key":"32488_CR15","doi-asserted-by":"publisher","unstructured":"Kohlenberg, A. et al. Candida auris: epidemiological situation, laboratory capacity and preparedness in European union and European economic area countries, 2013 to 2017. Eurosurveillance 23 https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.13.18-00136 (2018).","DOI":"10.2807\/1560-7917.ES.2018.23.13.18-00136"},{"key":"32488_CR16","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1128\/AAC.04867-14","volume":"59","author":"CJ Arnold","year":"2015","unstructured":"Arnold, C. J. et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. Antimicrob. Agents Chemother. 59, 2365\u20132373. https:\/\/doi.org\/10.1128\/AAC.04867-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"32488_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1128\/JCM.43.4.1829-1835.2005","volume":"43","author":"B Almirante","year":"2005","unstructured":"Almirante, B. et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43, 1829\u20131835. https:\/\/doi.org\/10.1128\/JCM.43.4.1829-1835.2005 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"32488_CR18","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1007\/s00134-009-1582-5","volume":"35","author":"A Caricato","year":"2009","unstructured":"Caricato, A. et al. Risk factors and outcome of acinetobacter baumanii infection in severe trauma patients. Intensive Care Med. 35, 1964\u20131969. https:\/\/doi.org\/10.1007\/s00134-009-1582-5 (2009).","journal-title":"Intensive Care Med."},{"key":"32488_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1445-5994.2005.00925.x","volume":"35","author":"JY Choi","year":"2005","unstructured":"Choi, J. Y. et al. Mortality risk factors of acinetobacter baumannii bacteraemia. Intern. Med. J. 35, 599\u2013603. https:\/\/doi.org\/10.1111\/j.1445-5994.2005.00925.x (2005).","journal-title":"Intern. Med. J."},{"key":"32488_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1179\/joc.2009.21.3.290","volume":"21","author":"AA Alsultan","year":"2009","unstructured":"Alsultan, A. A., Hamouda, A., Evans, B. A. & Amyes, S. G. B. Acinetobacter baumannii: emergence of four strains with NovelblaOXA\u201351\u2013likeGenes in patients with diabetes mellitus. J. Chemother. 21, 290\u2013295. https:\/\/doi.org\/10.1179\/joc.2009.21.3.290 (2009).","journal-title":"J. Chemother."},{"key":"32488_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1590\/s1413-86702012000300004","volume":"16","author":"ML Prata-Rocha","year":"2012","unstructured":"Prata-Rocha, M. L., Gontijo-Filho, P. P. & de Melo, G. B. Factors influencing survival in patients with multidrug-resistant acinetobacter baumannii infection. Brazilian J. Infect. Dis. 16, 237\u2013241. https:\/\/doi.org\/10.1590\/s1413-86702012000300004 (2012).","journal-title":"Brazilian J. Infect. Dis."},{"key":"32488_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s0891-5520(05)70363-9","volume":"11","author":"WL Wright","year":"1997","unstructured":"Wright, W. L. & Wenzel, R. P. Nosocomial Candida. Infect. Dis. Clin. North. Am. 11, 411\u2013425. https:\/\/doi.org\/10.1016\/s0891-5520(05)70363-9 (1997).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"32488_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3201\/eid1301.060716","volume":"13","author":"RH Sunenshine","year":"2007","unstructured":"Sunenshine, R. H. et al. Multidrug-resistant acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis. 13, 97\u2013103. https:\/\/doi.org\/10.3201\/eid1301.060716 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"32488_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/003655401750065544","volume":"33","author":"BM Joseph Baran Jr","year":"2001","unstructured":"Joseph Baran, B. M. Jr Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand. J. Infect. Dis. 33, 137\u2013139. https:\/\/doi.org\/10.1080\/003655401750065544 (2001).","journal-title":"Scand. J. Infect. Dis."},{"key":"32488_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archsurg.134.6.657","volume":"134","author":"AP Borzotta","year":"1999","unstructured":"Borzotta, A. P. Candida infections in critically ill trauma patients. Arch. Surg. 134, 657. https:\/\/doi.org\/10.1001\/archsurg.134.6.657 (1999).","journal-title":"Arch. Surg."},{"key":"32488_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/s0002-9343(89)80392-4","volume":"87","author":"J Bross","year":"1989","unstructured":"Bross, J., Talbot, G. H., Maislin, G., Hurwitz, S. & Strom, B. L. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia. Am. J. Med. 87, 614\u2013620. https:\/\/doi.org\/10.1016\/s0002-9343(89)80392-4 (1989).","journal-title":"Am. J. Med."},{"key":"32488_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/clind\/15.3.414","volume":"15","author":"VJ Fraser","year":"1992","unstructured":"Fraser, V. J. et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15, 414\u2013421. https:\/\/doi.org\/10.1093\/clind\/15.3.414 (1992).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR28","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1086\/313450","volume":"29","author":"AS Kao","year":"1999","unstructured":"Kao, A. S. et al. The epidemiology of candidemia in two united States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29, 1164\u20131170. https:\/\/doi.org\/10.1086\/313450 (1999).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s001340050286","volume":"23","author":"J Nolla-Salas","year":"1997","unstructured":"Nolla-Salas, J. et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med. 23, 23\u201330. https:\/\/doi.org\/10.1007\/s001340050286 (1997).","journal-title":"Intensive Care Med."},{"key":"32488_CR30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1164\/ajrccm.156.2.9612023","volume":"156","author":"M El-ebiary","year":"1997","unstructured":"El-ebiary, M. et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. Am. J. Respir Crit. Care Med. 156, 583\u2013590. https:\/\/doi.org\/10.1164\/ajrccm.156.2.9612023 (1997).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"32488_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1099\/jmm.0.000254","volume":"65","author":"KE da Silva","year":"2016","unstructured":"da Silva, K. E. et al. Risk factors for KPC-producing Klebsiella pneumoniae: watch out for surgery. J. Med. Microbiol. 65, 547\u2013553. https:\/\/doi.org\/10.1099\/jmm.0.000254 (2016).","journal-title":"J. Med. Microbiol."},{"key":"32488_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.bjid.2012.08.006","volume":"16","author":"FF Tuon","year":"2012","unstructured":"Tuon, F. F. et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Brazilian J. Infect. Dis. 16, 416\u2013419. https:\/\/doi.org\/10.1016\/j.bjid.2012.08.006 (2012).","journal-title":"Brazilian J. Infect. Dis."},{"key":"32488_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jhin.2017.02.010","volume":"96","author":"KM Cronin","year":"2017","unstructured":"Cronin, K. M. et al. Risk factors for KPC-producing Enterobacteriaceae acquisition and infection in a healthcare setting with possible local transmission: a case\u2013control study. J. Hosp. Infect. 96, 111\u2013115. https:\/\/doi.org\/10.1016\/j.jhin.2017.02.010 (2017).","journal-title":"J. Hosp. Infect."},{"key":"32488_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1155\/2011\/827692","volume":"18","author":"M-S Delisle","year":"2011","unstructured":"Delisle, M-S. et al. Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia. Can. Respir J. 18, 131\u2013136. https:\/\/doi.org\/10.1155\/2011\/827692 (2011).","journal-title":"Can. Respir J."},{"key":"32488_CR35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1086\/374339","volume":"36","author":"H Wisplinghoff","year":"2003","unstructured":"Wisplinghoff, H., Seifert, H., Wenzel, R. P. & Edmond, M. B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the united States. Clin. Infect. Dis. 36, 1103\u20131110. https:\/\/doi.org\/10.1086\/374339 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309\u2013317. https:\/\/doi.org\/10.1086\/421946 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR37","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/01.inf.0000078159.53132.40","volume":"22","author":"H Wisplinghoff","year":"2003","unstructured":"Wisplinghoff, H. et al. Nosocomial bloodstream infections in pediatric patients in united States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J. 22, 686\u2013691. https:\/\/doi.org\/10.1097\/01.inf.0000078159.53132.40 (2003).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"32488_CR38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1080\/23744235.2019.1662941","volume":"51","author":"M Ala-Houhala","year":"2019","unstructured":"Ala-Houhala, M., Valkonen, M., Kolho, E., Friberg, N. & Anttila, V-J. Clinical and Microbiological factors associated with mortality in candidemia in adult patients 2007\u20132016. Infect. Dis. (Lond). 51, 824\u2013830. https:\/\/doi.org\/10.1080\/23744235.2019.1662941 (2019).","journal-title":"Infect. Dis. (Lond)"},{"key":"32488_CR39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","volume":"40","author":"O Lortholary","year":"2014","unstructured":"Lortholary, O. et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010). Intensive Care Med. 40, 1303\u20131312. https:\/\/doi.org\/10.1007\/s00134-014-3408-3 (2014).","journal-title":"Intensive Care Med."},{"key":"32488_CR40","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/319613","volume":"32","author":"LG Miller","year":"2001","unstructured":"Miller, L. G., Hajjeh, R. A. & Edwards, J. E. Estimating the cost of nosocomial candidemia in the united States. Clin. Infect. Dis. 32, 1110\u20131110. https:\/\/doi.org\/10.1086\/319613 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1524-4733.2002.51108.x","volume":"5","author":"LS Wilson","year":"2002","unstructured":"Wilson, L. S. et al. The direct cost and incidence of systemic fungal infections. Value Health. 5, 26\u201334. https:\/\/doi.org\/10.1046\/j.1524-4733.2002.51108.x (2002).","journal-title":"Value Health"},{"key":"32488_CR42","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1086\/496922","volume":"41","author":"TE Zaoutis","year":"2005","unstructured":"Zaoutis, T. E. et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the united states: a propensity analysis. Clin. Infect. Dis. 41, 1232\u20131239. https:\/\/doi.org\/10.1086\/496922 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jgar.2020.06.003","volume":"22","author":"A Chowdhary","year":"2020","unstructured":"Chowdhary, A. & Sharma, A. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic. J. Glob Antimicrob. Resist. 22, 175\u2013176. https:\/\/doi.org\/10.1016\/j.jgar.2020.06.003 (2020).","journal-title":"J. Glob Antimicrob. Resist."},{"key":"32488_CR44","doi-asserted-by":"publisher","unstructured":"Lockhart, S. R. et al. Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clinical Infectious Diseases. 2017;64: 134\u2013140. (2016). \/12\/19 https:\/\/doi.org\/10.1093\/cid\/ciw691","DOI":"10.1093\/cid\/ciw691"},{"key":"32488_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0196-6553(82)90003-7","volume":"10","author":"MA Strassburg","year":"1982","unstructured":"Strassburg, M. A. The global eradication of smallpox. Am. J. Infect. Control. 10, 53\u201359. https:\/\/doi.org\/10.1016\/0196-6553(82)90003-7 (1982).","journal-title":"Am. J. Infect. Control"},{"key":"32488_CR46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1128\/EC.00279-10","volume":"10","author":"Y Liu","year":"2011","unstructured":"Liu, Y. & Filler, S. G. Candida albicans Als3, a multifunctional adhesin and Invasin. Eukaryot. Cell. 10, 168\u2013173. https:\/\/doi.org\/10.1128\/EC.00279-10 (2011).","journal-title":"Eukaryot. Cell."},{"key":"32488_CR47","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1371\/journal.pbio.0050064","volume":"5","author":"QT Phan","year":"2007","unstructured":"Phan, Q. T. et al. Als3 is a Candida albicans Invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol. 5, e64. https:\/\/doi.org\/10.1371\/journal.pbio.0050064 (2007).","journal-title":"PLoS Biol."},{"key":"32488_CR48","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1128\/IAI.00013-13","volume":"81","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. Investigation of the function of Candida albicans Als3 by heterologous expression in Candida glabrata. Infect. Immun. 81, 2528\u20132535. https:\/\/doi.org\/10.1128\/IAI.00013-13 (2013).","journal-title":"Infect. Immun."},{"key":"32488_CR49","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1086\/652407","volume":"201","author":"G Luo","year":"2010","unstructured":"Luo, G. et al. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J. Infect. Dis. 201, 1718\u20131728. https:\/\/doi.org\/10.1086\/652407 (2010).","journal-title":"J. Infect. Dis."},{"key":"32488_CR50","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3389\/fimmu.2018.01349","volume":"9","author":"P Uppuluri","year":"2018","unstructured":"Uppuluri, P. et al. Human Anti-Als3p antibodies are surrogate markers of NDV-3A vaccine efficacy against recurrent vulvovaginal candidiasis. Front. Immunol. 9, 1349. https:\/\/doi.org\/10.3389\/fimmu.2018.01349 (2018).","journal-title":"Front. Immunol."},{"key":"32488_CR51","doi-asserted-by":"publisher","unstructured":"Alqarihi, A., Singh, S., Edwards, J. E., Ibrahim, A. S. & Uppuluri, P. NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice. Sci. Rep. 9 https:\/\/doi.org\/10.1038\/s41598-019-42517-y (2019).","DOI":"10.1038\/s41598-019-42517-y"},{"key":"32488_CR52","doi-asserted-by":"publisher","unstructured":"Uppuluri, P. et al. The Hyr1 protein from the fungus Candida albicans is a cross Kingdom immunotherapeutic target for acinetobacter bacterial infection. PLoS Pathog. 14 https:\/\/doi.org\/10.1371\/journal.ppat.1007056 (2018).","DOI":"10.1371\/journal.ppat.1007056"},{"key":"32488_CR53","doi-asserted-by":"publisher","unstructured":"Ibrahim, A. S. et al. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine 31, 5549\u20135556. https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.016 (2013).","DOI":"10.1016\/j.vaccine.2013.09.016"},{"key":"32488_CR54","doi-asserted-by":"publisher","unstructured":"Edwards, J. E. et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal Candidiasis-A phase 2 Randomized, Double-Blind, Placebo-Controlled trial. Clinical Infectious Diseases. 2018\/04\/27. ;66: 1928\u20131936. (2018). https:\/\/doi.org\/10.1093\/cid\/ciy185","DOI":"10.1093\/cid\/ciy185"},{"key":"32488_CR55","doi-asserted-by":"publisher","first-page":"e1007460","DOI":"10.1371\/journal.ppat.1007460","volume":"15","author":"S Singh","year":"2019","unstructured":"Singh, S. et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. Gaffen SL, editor. PLoS Pathog. 15, e1007460. https:\/\/doi.org\/10.1371\/journal.ppat.1007460 (2019).","journal-title":"PLoS Pathog"},{"key":"32488_CR56","doi-asserted-by":"publisher","unstructured":"Smoak, R. A., Snyder, L. F., Fassler, J. S. & He, B. Z. Parallel expansion and divergence of an adhesin family in pathogenic yeasts. Mitchell A, editor. Genetics. ;223. (2023). https:\/\/doi.org\/10.1093\/genetics\/iyad024","DOI":"10.1093\/genetics\/iyad024"},{"key":"32488_CR57","doi-asserted-by":"publisher","unstructured":"Singh, S. et al. Protective efficacy of Anti-Hyr1p monoclonal antibody against systemic candidiasis due to Multi-Drug-Resistant Candida auris. J. Fungi (Basel). 9 https:\/\/doi.org\/10.3390\/jof9010103 (2023).","DOI":"10.3390\/jof9010103"},{"key":"32488_CR58","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1038\/s41467-018-07738-1","volume":"9","author":"FM Rudkin","year":"2018","unstructured":"Rudkin, F. M. et al. Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. Nat. Commun. 9, 5288. https:\/\/doi.org\/10.1038\/s41467-018-07738-1 (2018).","journal-title":"Nat. Commun."},{"key":"32488_CR59","doi-asserted-by":"publisher","unstructured":"Bing, J. et al. Clinical isolates of Candida auris with enhanced adherence and biofilm formation due to genomic amplification of ALS4. PLoS Pathog. 19 https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1011239 (2023).","DOI":"10.1371\/JOURNAL.PPAT.1011239"},{"key":"32488_CR60","doi-asserted-by":"publisher","first-page":"9212","DOI":"10.1038\/S41467-024-53588-5","volume":"15","author":"TW Wang","year":"2024","unstructured":"Wang, T. W. et al. Functional redundancy in Candida auris cell surface adhesins crucial for cell-cell interaction and aggregation. Nat. Commun. 15, 9212. https:\/\/doi.org\/10.1038\/S41467-024-53588-5 (2024).","journal-title":"Nat. Commun."},{"key":"32488_CR61","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.adf8972","volume":"381","author":"DJ Santana","year":"2023","unstructured":"Santana, D. J. et al. A Candida auris-specific adhesin, Scf1, governs surface association, colonization, and virulence. Science 381, 1461\u20131467. https:\/\/doi.org\/10.1126\/science.adf8972 (2023).","journal-title":"Science"},{"key":"32488_CR62","doi-asserted-by":"publisher","unstructured":"Christensen, D. Development and evaluation of CAF01. Immunopotentiators in modern vaccines. Second Ed. 333\u2013345. https:\/\/doi.org\/10.1016\/B978-0-12-804019-5.00017-7 (2017).","DOI":"10.1016\/B978-0-12-804019-5.00017-7"},{"key":"32488_CR63","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","volume":"32","author":"JT van Dissel","year":"2014","unstructured":"van Dissel, J. T. et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 32, 7098\u20137107. https:\/\/doi.org\/10.1016\/j.vaccine.2014.10.036 (2014).","journal-title":"Vaccine"},{"key":"32488_CR64","doi-asserted-by":"publisher","first-page":"9772","DOI":"10.1038\/S41598-022-13819-5","volume":"12","author":"FC Stark","year":"2022","unstructured":"Stark, F. C. et al. Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 Spike protein-based vaccine is Immunogenic and efficacious in mice and hamsters. Sci. Rep. 12, 9772. https:\/\/doi.org\/10.1038\/S41598-022-13819-5 (2022).","journal-title":"Sci. Rep."},{"key":"32488_CR65","doi-asserted-by":"publisher","unstructured":"Hung, C. Y. et al. Glucan-chitin particles enhance Th17 response and improve protective efficacy of a multivalent antigen (rCpa1) against pulmonary coccidioides posadasii infection. Infect. Immun. 86 https:\/\/doi.org\/10.1128\/iai.00070-18\/asset\/7fd23acf-731c-4cd9-a8ad-00146a476031\/assets\/graphic\/zii9990925720008.jpeg (2018).","DOI":"10.1128\/iai.00070-18\/asset\/7fd23acf-731c-4cd9-a8ad-00146a476031\/assets\/graphic\/zii9990925720008.jpeg"},{"key":"32488_CR66","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/0264-410X(95)00089-J","volume":"13","author":"G Ott","year":"1995","unstructured":"Ott, G., Barchfeld, G. L., Nest, G. & Van Enhancement of humoral response against human influenza vaccine with the simple submicron oil\/water emulsion adjuvant MF59. Vaccine 13, 1557\u20131562. https:\/\/doi.org\/10.1016\/0264-410X(95)00089-J (1995).","journal-title":"Vaccine"},{"key":"32488_CR67","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/0264-410X(93)90376-9","volume":"11","author":"W Keitel","year":"1993","unstructured":"Keitel, W. et al. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11, 909\u2013913. https:\/\/doi.org\/10.1016\/0264-410X(93)90376-9 (1993).","journal-title":"Vaccine"},{"key":"32488_CR68","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1128\/iai.00142-06;subpage:string:full","volume":"74","author":"T Bader","year":"2006","unstructured":"Bader, T. et al. Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain. Infect. Immun. 74, 4366\u20134369. https:\/\/doi.org\/10.1128\/iai.00142-06;subpage:string:full (2006).","journal-title":"Infect. Immun."},{"key":"32488_CR69","doi-asserted-by":"publisher","first-page":"2206713","DOI":"10.1002\/ADVS.202206713","volume":"10","author":"L Lin","year":"2023","unstructured":"Lin, L. et al. Sequence variation of Candida albicans Sap2 enhances fungal pathogenicity via complement evasion and macrophage M2-like phenotype induction. Adv. Sci. 10, 2206713. https:\/\/doi.org\/10.1002\/ADVS.202206713 (2023).","journal-title":"Adv. Sci."},{"key":"32488_CR70","doi-asserted-by":"publisher","first-page":"e64482","DOI":"10.1371\/journal.pone.0064482","volume":"8","author":"A L\u00fcttich","year":"2013","unstructured":"L\u00fcttich, A., Brunke, S., Hube, B. & Jacobsen, I. D. Serial passaging of Candida albicans in systemic murine infection suggests that the wild type strain SC5314 is well adapted to the murine kidney. PLoS One. 8, e64482. https:\/\/doi.org\/10.1371\/journal.pone.0064482 (2013).","journal-title":"PLoS One"},{"key":"32488_CR71","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1128\/IAI.74.5.3039-3041.2006","volume":"74","author":"AS Ibrahim","year":"2006","unstructured":"Ibrahim, A. S., Spellberg, B. J., Avanesian, V., Fu, Y. & Edwards, J. E. The anti-candida vaccine based on the Recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect. Immun. 74, 3039\u20133041. https:\/\/doi.org\/10.1128\/IAI.74.5.3039-3041.2006 (2006). 2006\/04\/20.","journal-title":"Infect. Immun."},{"key":"32488_CR72","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1128\/IAI.73.9.6191-6193.2005","volume":"73","author":"BJ Spellberg","year":"2005","unstructured":"Spellberg, B. J. et al. The anti-Candida albicans vaccine composed of the Recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect. Immun. 73, 6191\u20136193. https:\/\/doi.org\/10.1128\/IAI.73.9.6191-6193.2005 (2005).","journal-title":"Infect. Immun."},{"key":"32488_CR73","doi-asserted-by":"publisher","unstructured":"Cao, H. et al. An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. Vaccines. 9, 1261. 2021;9: 1261. (2021). https:\/\/doi.org\/10.3390\/vaccines9111261","DOI":"10.3390\/vaccines9111261"},{"key":"32488_CR74","doi-asserted-by":"publisher","first-page":"419658","DOI":"10.3389\/fcimb.2019.00031\/bibtex","volume":"9","author":"T Ebensen","year":"2019","unstructured":"Ebensen, T., Delandre, S., Prochnow, B., Guzm\u00e1n, C. A. & Schulze, K. The combination vaccine adjuvant system alum\/c-di-AMP results in quantitative and qualitative enhanced immune responses post immunization. Front. Cell. Infect. Microbiol. 9, 419658. https:\/\/doi.org\/10.3389\/fcimb.2019.00031\/bibtex (2019).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"32488_CR75","doi-asserted-by":"publisher","unstructured":"Lin, L. et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009;5: e1000703. (2009). \/12\/31 https:\/\/doi.org\/10.1371\/journal.ppat.1000703","DOI":"10.1371\/journal.ppat.1000703"},{"key":"32488_CR76","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/eji.201041226","volume":"41","author":"FL van de Veerdonk","year":"2011","unstructured":"van de Veerdonk, F. L. et al. The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. Eur. J. Immunol. 41, 2260\u20132268. https:\/\/doi.org\/10.1002\/eji.201041226 (2011).","journal-title":"Eur. J. Immunol."},{"key":"32488_CR77","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2019.01.041","volume":"176","author":"P Bacher","year":"2019","unstructured":"Bacher, P. et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. Cell 176, 1340\u20131355e15. https:\/\/doi.org\/10.1016\/j.cell.2019.01.041 (2019).","journal-title":"Cell"},{"key":"32488_CR78","doi-asserted-by":"publisher","unstructured":"Datta, A. et al. Differential skin immune responses in mice intradermally infected with Candida auris and Candida albicans. Obar JJ, editor. Microbiol Spectr. ; e0221523. (2023). https:\/\/doi.org\/10.1128\/spectrum.02215-23","DOI":"10.1128\/spectrum.02215-23"},{"key":"32488_CR79","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.chom.2020.12.002","volume":"29","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. Murine model of colonization with fungal pathogen Candida auris to explore skin tropism, host risk factors and therapeutic strategies. Cell. Host Microbe. 29, 210\u2013221e6. https:\/\/doi.org\/10.1016\/j.chom.2020.12.002 (2021).","journal-title":"Cell. Host Microbe"},{"key":"32488_CR80","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1086\/529204","volume":"197","author":"B Spellberg","year":"2008","unstructured":"Spellberg, B. et al. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J. Infect. Dis. 197, 967\u2013971. https:\/\/doi.org\/10.1086\/529204 (2008).","journal-title":"J. Infect. Dis."},{"key":"32488_CR81","doi-asserted-by":"publisher","unstructured":"Spellberg, B. J. et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. Journal of Infectious Diseases. 2006;194: 256\u2013260. (2006). \/06\/17 https:\/\/doi.org\/10.1086\/504691","DOI":"10.1086\/504691"},{"key":"32488_CR82","doi-asserted-by":"publisher","unstructured":"Seo, H., Duan, Q., Upadhyay, I. & Zhang, W. Evaluation of multivalent enterotoxigenic Escherichia coli vaccine candidate Mecvax antigen dose-dependent effect in a murine model. Appl. Environ. Microbiol. 88 https:\/\/doi.org\/10.1128\/AEM.00959-22 (2022).","DOI":"10.1128\/AEM.00959-22"},{"key":"32488_CR83","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0264-410X(99)00316-3","volume":"18","author":"SK Kim","year":"1999","unstructured":"Kim, S. K. et al. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 18, 597\u2013603. https:\/\/doi.org\/10.1016\/S0264-410X(99)00316-3 (1999).","journal-title":"Vaccine"},{"key":"32488_CR84","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/J.VACCINE.2007.11.054","volume":"26","author":"A Wack","year":"2008","unstructured":"Wack, A. et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26, 552\u2013561. https:\/\/doi.org\/10.1016\/J.VACCINE.2007.11.054 (2008).","journal-title":"Vaccine"},{"key":"32488_CR85","doi-asserted-by":"crossref","unstructured":"Bays, D. J. et al. Epidemiology of invasive candidiasis. Clin. Epidemiol. 16, 549\u2013566. https:\/\/doi.org\/10.2147\/Clep.S459600\/Asset\/6e086104-64f7-4e78-A6b3- (2024).\u00a0","DOI":"10.2147\/CLEP.S459600"},{"key":"32488_CR86","unstructured":"Tracking Candida auris. In: Centers for disease control and prevention [Internet]. USA: Centers for Disease Control and Prevention. (2019). Available: https:\/\/www.cdc.gov\/fungal\/candida-auris\/tracking-c-auris.html"},{"key":"32488_CR87","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3201\/EID3108.250315","volume":"31","author":"AD Baker","year":"2025","unstructured":"Baker, A. D., Gold, J. A. W., Forsberg, K., Jones, S. & Lyman, M. M. Progression from Candida auris colonization screening to clinical case Status, united States, 2016\u20132023. 31, 8, 2025 - Emerging infectious diseases journal - CDC. Emerg. Infect. Dis. 31, 1613\u20131617. https:\/\/doi.org\/10.3201\/EID3108.250315 (2025).","journal-title":"Emerg. Infect. Dis."},{"key":"32488_CR88","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.4049\/jimmunol.1600965","volume":"198","author":"R Billeskov","year":"2017","unstructured":"Billeskov, R. et al. Low antigen dose in adjuvant-based vaccination selectively induces CD4 T cells with enhanced functional avidity and protective efficacy. J. Immunol. 198, 3494\u20133506. https:\/\/doi.org\/10.4049\/jimmunol.1600965 (2017).","journal-title":"J. Immunol."},{"key":"32488_CR89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1084\/JEM.132.1.77","volume":"132","author":"B Andersson","year":"1970","unstructured":"Andersson, B. Studies on the regulation of avidity at the level of the single antibody-forming cell the effect of antigen dose and time after immunization. J. Exp. Med. 132, 77\u201388. https:\/\/doi.org\/10.1084\/JEM.132.1.77 (1970).","journal-title":"J. Exp. Med."},{"key":"32488_CR90","doi-asserted-by":"publisher","first-page":"e00339","DOI":"10.1128\/msphere.00339-19","volume":"4","author":"H Xin","year":"2019","unstructured":"Xin, H., Mohiuddin, F., Tran, J., Adams, A. & Eberle, K. Experimental mouse models of disseminated Candida auris infection. mSphere 4, e00339\u2013e00319. https:\/\/doi.org\/10.1128\/msphere.00339-19 (2019).","journal-title":"mSphere"},{"key":"32488_CR91","doi-asserted-by":"publisher","unstructured":"Forg\u00e1cs, L. et al. Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model. Emerg. Microbes Infect. 9, 1160\u20131169. https:\/\/doi.org\/10.1080\/22221751.2020.1771218;journal (2020).","DOI":"10.1080\/22221751.2020.1771218;journal"},{"key":"32488_CR92","doi-asserted-by":"publisher","first-page":"e0310152","DOI":"10.1371\/journal.pone.0310152","volume":"19","author":"S Ghosh","year":"2024","unstructured":"Ghosh, S., Banerjee, M. & Chattopadhyay, A. K. Effect of vaccine dose intervals: considering immunity levels, vaccine efficacy, and strain variants for disease control strategy. PLoS One. 19, e0310152. https:\/\/doi.org\/10.1371\/journal.pone.0310152 (2024).","journal-title":"PLoS One"},{"key":"32488_CR93","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/CID\/CIAE559","volume":"80","author":"JP Townsend","year":"2025","unstructured":"Townsend, J. P., Hassler, H. B., Dornburg, A. & Optimal Annual COVID-19 vaccine boosting dates following previous booster vaccination or breakthrough infection. Clin. Infect. Dis. 80, 316\u2013322. https:\/\/doi.org\/10.1093\/CID\/CIAE559 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR94","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/JMV.27637","volume":"94","author":"N Luan","year":"2022","unstructured":"Luan, N., Wang, Y., Cao, H., Lin, K. & Liu, C. Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS\u2010CoV\u20102 vaccine in mice. J. Med. Virol. 94, 2250. https:\/\/doi.org\/10.1002\/JMV.27637 (2022).","journal-title":"J. Med. Virol."},{"key":"32488_CR95","doi-asserted-by":"publisher","first-page":"8426","DOI":"10.1038\/S41598-024-58811-3","volume":"14","author":"CS Korosec","year":"2024","unstructured":"Korosec, C. S., Dick, D. W., Moyles, I. R. & Watmough, J. SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series. Sci. Rep. 14, 8426. https:\/\/doi.org\/10.1038\/S41598-024-58811-3 (2024).","journal-title":"Sci. Rep."},{"key":"32488_CR96","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/21645515.2018.1527496","volume":"15","author":"R Billeskov","year":"2018","unstructured":"Billeskov, R., Beikzadeh, B. & Berzofsky, J. A. The effect of antigen dose on T cell-targeting vaccine outcome. Hum. Vaccin Immunother. 15, 407. https:\/\/doi.org\/10.1080\/21645515.2018.1527496 (2018).","journal-title":"Hum. Vaccin Immunother"},{"key":"32488_CR97","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/J.MIB.2020.05.006","volume":"56","author":"CA Kumamoto","year":"2020","unstructured":"Kumamoto, C. A., Gresnigt, M. S. & Hube, B. The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Curr. Opin. Microbiol. 56, 7\u201315. https:\/\/doi.org\/10.1016\/J.MIB.2020.05.006 (2020).","journal-title":"Curr. Opin. Microbiol."},{"key":"32488_CR98","doi-asserted-by":"publisher","first-page":"1820292","DOI":"10.1080\/20002297.2020.1820292","volume":"12","author":"\u00c2 Ger\u00f3s-Mesquita","year":"2020","unstructured":"Ger\u00f3s-Mesquita, \u00c2. et al. Oral Candida albicans colonization in healthy individuals: prevalence, genotypic diversity, stability along time and transmissibility. J. Oral Microbiol. 12, 1820292. https:\/\/doi.org\/10.1080\/20002297.2020.1820292 (2020).","journal-title":"J. Oral Microbiol."},{"key":"32488_CR99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/J.1600-0714.2007.00574.X","volume":"37","author":"S G\u00fcnd\u00fcz Arslan","year":"2008","unstructured":"G\u00fcnd\u00fcz Arslan, S., Akpolat, N., Kama, J. D., \u00d6zer, T. & Hamamci, O. One-year follow-up of the effect of fixed orthodontic treatment on colonization by oral Candida. J. Oral Pathol. Med. 37, 26\u201329. https:\/\/doi.org\/10.1111\/J.1600-0714.2007.00574.X (2008).","journal-title":"J. Oral Pathol. Med."},{"key":"32488_CR100","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S1473-3099(24)00147-6","volume":"24","author":"KM Pollock","year":"2024","unstructured":"Pollock, K. M. et al. An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial. Lancet Infect. Dis. 24, 829\u2013844. https:\/\/doi.org\/10.1016\/S1473-3099(24)00147-6 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"32488_CR101","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/cid\/ciy1087","volume":"69","author":"JC Dejon-Agobe","year":"2019","unstructured":"Dejon-Agobe, J. C. et al. Controlled human malaria infection of healthy adults with lifelong malaria exposure to assess Safety, Immunogenicity, and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. Clin. Infect. Dis. 69, 1377\u20131384. https:\/\/doi.org\/10.1093\/cid\/ciy1087 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"32488_CR102","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1089\/aid.2013.0076","volume":"29","author":"VRG Rom\u00e1n","year":"2013","unstructured":"Rom\u00e1n, V. R. G. et al. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant t cell epitopes: Safety, immunogenicity, and feasibility in guinea-Bissau. AIDS Res. Hum. Retroviruses. 29, 1504\u20131512. https:\/\/doi.org\/10.1089\/aid.2013.0076 (2013).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"32488_CR103","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1473-3099(19)30279-8","volume":"19","author":"S Abraham","year":"2019","unstructured":"Abraham, S. et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect. Dis. 19, 1091\u20131100. https:\/\/doi.org\/10.1016\/S1473-3099(19)30279-8 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"32488_CR104","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1128\/IAI.73.2.999-1005.2005","volume":"73","author":"AS Ibrahim","year":"2005","unstructured":"Ibrahim, A. S. et al. Vaccination with Recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 73, 999\u20131005. https:\/\/doi.org\/10.1128\/IAI.73.2.999-1005.2005 (2005).","journal-title":"Infect. Immun."},{"key":"32488_CR105","doi-asserted-by":"publisher","first-page":"348","DOI":"10.14744\/NCI.2020.27136","volume":"7","author":"AU Kilic","year":"2020","unstructured":"Kilic, A. U. et al. Risk prediction for candidemia in surgical intensive care unit patients. North. Clin. Istanb. 7, 348. https:\/\/doi.org\/10.14744\/NCI.2020.27136 (2020).","journal-title":"North. Clin. Istanb"},{"key":"32488_CR106","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1080\/21645515.2015.1044167","volume":"11","author":"T Vesikari","year":"2015","unstructured":"Vesikari, T., Forst\u00e9n, A., Arora, A., Tsai, T. & Clemens, R. Influenza vaccination in children primed with MF59\u00ae-adjuvanted or non-adjuvanted seasonal influenza vaccine. Hum. Vaccine Immunother. 11, 2102\u20132112. https:\/\/doi.org\/10.1080\/21645515.2015.1044167 (2015).","journal-title":"Hum. Vaccine Immunother"},{"key":"32488_CR107","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1086\/430952","volume":"192","author":"B Spellberg","year":"2005","unstructured":"Spellberg, B., Ibrahim, A. S., Edwards, J. E. & Filler, S. G. Mice with disseminated candidiasis die of progressive sepsis. J. Infect. Dis. 192, 336\u2013343. https:\/\/doi.org\/10.1086\/430952 (2005).","journal-title":"J. Infect. Dis."},{"key":"32488_CR108","doi-asserted-by":"publisher","unstructured":"Luo, G., Ibrahim, A. S., French, S. W., Edwards, J. E. & Fu, Y. Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PLoS One. 6 https:\/\/doi.org\/10.1371\/journal.pone.0025909 (2011).","DOI":"10.1371\/journal.pone.0025909"},{"key":"32488_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000410","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. https:\/\/doi.org\/10.1371\/journal.pbio.3000410 (2020).","journal-title":"PLoS Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32488-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32488-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32488-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:03:09Z","timestamp":1769216589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32488-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32488"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32488-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7270678\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.S.I. is a founder of Vitalex Biosciences, which is developing a Candida dual antigen vaccine targeting healthcare-associated pathogens. S.S., T.G., S.A. and T.C. are shareholders of Vitalex Biosciences. The rest of the authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The IACUC of The Lundquist Institute approved all procedures involving mice (protocol #31413-02), in accordance with the NIH guidelines for animal housing and care and the ARRIVE guidelines\n                      109\n                      . Moribund mice, according to detailed and well-characterized criteria, were euthanized by pentobarbital overdose, followed by cervical dislocation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}],"article-number":"2582"}}